A systems-level operator across product, technology, and commercial (with a One Peak- and Morgan Stanley-backed exit behind me). The through-line is durability.
Engagements usually start small: a single diligence read, or a half-day with a portfolio company's product leadership. They grow from there if they're useful.
Reading a target's product and technology the way the Durability Stack reads a moat: what's genuinely defensible, what the customer or a competitor can reclaim, where the real AI exposure sits, past the surface "it's SaaS, so it's exposed" read.
One example of what that surfaces: almost no vendor today can show which work was done by an AI agent and who is accountable for it. It scores nothing in a feature comparison, so it appears on no scorecard. It becomes a priced gap at exit. That's the class of finding a durability read is looking for.
Recent diligence for global and European funds sits under NDA.
A standing sounding board to the fund on product and technology, across pipeline and portfolio.
Working directly with portfolio-company product and tech leaders on CPTO-level strategy where a fund wants hands-on support, not a report.
Regular consultations through expert networks, such as Third Bridge, AlphaSights and Dialectica, usually M&A-driven. Where the technology actually stands, how the vendor landscape is really shaped, which players are stronger or weaker than the market assumes.
A peer who's held the seat — CTO first, then CPO / CPTO — and been through the exit, bringing the investor's-eye view back to the operator's side of the table.
A formal seat with a scale-up, bringing product, technology, and commercial judgment.
A senior peer to pressure-test product and technology strategy with, whether you're a CPO, CPTO, or a CEO carrying product.
Helping a leadership team make their durability legible before investors stress-test it.
I read product, technology, and the commercial logic connecting them. I don't run code, security, or infrastructure audits: a full technical DD needs a specialist alongside me, and I'll say so early rather than late.
My regulated-industry depth is European mid-market EHS, ESG, and quality and integrated management systems. The pharma and medical-device end of quality management (where systems have to be formally validated) is the adjacent neighbourhood, not mine.
I'm European. On US-market questions I'm a second opinion.
Worth a conversation?
Email is fastest. LinkedIn if you'd rather check the background first.